Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

BioCryst Pharmaceuticals Announces Presentation Of Forodesine Data At The 45th Annual Meeting Of The American Society Of Clinical Oncology
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced long-term data from a Phase 2 study of forodesine, the Company"s lead oncology compound, in patients with cutaneous T-cell lymphoma (CTCL). The data will be presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held in Orlando, Florida from May 29-June 2. Forodesine is a transition-state analog inhibitor of purine nucleoside phosphorylase (PNP), a purine salvage pathway enzyme that is essential for the proliferation of T-cells and B-cells.
generic viagra online
St. Jude Medical Completes Implants In U.S. Study Of Deep Brain Stimulation For Parkinson's Disease
St. Jude Medical, Inc. (NYSE:STJ) announced the completion of patient implants in its U.S. pivotal clinical study of deep brain stimulation (DBS) for the symptomatic treatment of Parkinson"s disease, a neurological disorder affecting approximately 6.3 million people worldwide that progressively diminishes a person"s control over his or her movements. The announcement was made at the Movement Disorder Society"s 13th International Congress of Parkinson"s Disease and Movement Disorders in Paris.
News of the day
Inoperable Colon Cancer Responds To New Treatment
With an extensive, inoperable colon cancer and few options available, a Tennessee patient is seeing his cancer steadily regressing on a new outpatient treatment. Individuals from 26 U.S. states and four other countries have been among the first to use NeoPlas Innovation"s new protocol. The Tennessee patient"s early results mirror their successes in battling colon cancer and other very aggressive malignancies.
Cardiovascular

Technology To Improve Accuracy Of Ovarian Cancer Diagnosis

Moffitt Cancer Center and Frantz BioMarkers, LLC have signed a license agreement on phospholipid biomarkers of ovarian cancer. Frantz BioMarkers, which has been granted exclusive worldwide rights to Moffitt"s interests in the biomarkers, will pay initiation, developmental milestone and license maintenance fees, and royalties on sales. Moffitt and Frantz BioMarkers will collaborate on ovarian cancer biomarker research, combining use of these licensed markers with lipid markers developed independently by Frantz BioMarkers. Each year, 26,000 women in the United States are diagnosed with ovarian cancer, and 16,000 die of the disease. There is no effective screening tool or method for accurate diagnosis without surgery. Even among symptomatic women, surgery is the only reliable way to distinguish between benign and malignant disease. It is estimated that up to 5 percent of women in the United States will undergo surgery for a suspected ovarian neoplasm. More than two-thirds of women undergoing surgery for suspected ovarian malignancy do not have cancer. The only clinical blood biomarker available for diagnosis is CA125, which is unreliable, especially for accurate diagnosis at an early stage when a cure is feasible. Researchers at Moffitt and Frantz BioMarkers discovered that when CA125 is combined with selected phospholipids, the diagnostic accuracy for early stage ovarian cancer can significantly improve. More than 2,200 women donated blood samples for the research through the Tampa Bay Ovarian Cancer Coalition, a collaborative regional network. Frantz BioMarkers is developing these biomarkers into a clinical diagnostic test. Co-inventors of the technology are Dr. Rebecca Sutphen, director of Clinical Genetics at Moffitt, and Lorelei Davis, Ph.D., and Lian Shan, Ph.D., of Frantz BioMarkers. Michelle Foley H. Lee Moffitt Cancer Center & Research Institute


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009